Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Dare Bioscience (DARE) over the last 10 years, with Q3 2025 value amounting to -$151559.0.

  • Dare Bioscience's Capital Expenditures fell 13951.8% to -$151559.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $251632.0, marking a year-over-year decrease of 8039.29%. This contributed to the annual value of $749036.0 for FY2024, which is 1900.23% up from last year.
  • Dare Bioscience's Capital Expenditures amounted to -$151559.0 in Q3 2025, which was down 13951.8% from $172865.0 recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Capital Expenditures registered a high of $607331.0 during Q4 2023, and its lowest value of -$151559.0 during Q3 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $38551.0 (2022), whereas its average is $116764.0.
  • As far as peak fluctuations go, Dare Bioscience's Capital Expenditures skyrocketed by 2241876.16% in 2023, and later crashed by 13951.8% in 2025.
  • Over the past 5 years, Dare Bioscience's Capital Expenditures (Quarter) stood at $14524.0 in 2021, then crashed by 81.43% to $2697.0 in 2022, then skyrocketed by 22418.76% to $607331.0 in 2023, then tumbled by 87.98% to $72995.0 in 2024, then tumbled by 307.63% to -$151559.0 in 2025.
  • Its last three reported values are -$151559.0 in Q3 2025, $172865.0 for Q2 2025, and $157331.0 during Q1 2025.